X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (82) 82
oncology (67) 67
female (56) 56
index medicus (56) 56
male (47) 47
middle aged (47) 47
aged (39) 39
lung neoplasms - genetics (36) 36
adult (35) 35
respiratory system (35) 35
lung neoplasms - pathology (33) 33
carcinoma, non-small-cell lung - genetics (29) 29
prognosis (27) 27
lung neoplasms - drug therapy (25) 25
carcinoma, non-small-cell lung - pathology (24) 24
carcinoma, non-small-cell lung - drug therapy (22) 22
lung cancer (22) 22
chemotherapy (21) 21
immunohistochemistry (18) 18
mutation (18) 18
receptor, epidermal growth factor - genetics (18) 18
cancer (17) 17
lung cancer, non-small cell (17) 17
aged, 80 and over (16) 16
erlotinib (16) 16
neoplasm staging (16) 16
gefitinib (15) 15
non-small cell lung cancer (15) 15
care and treatment (13) 13
lung neoplasms - metabolism (13) 13
article (12) 12
follow-up studies (12) 12
treatment outcome (12) 12
receptor, epidermal growth factor - antagonists & inhibitors (11) 11
research (11) 11
adenocarcinoma (10) 10
beer (10) 10
biochemistry (10) 10
chemistry (10) 10
compositions or test papers therefor (10) 10
condition-responsive control in microbiological orenzymological processes (10) 10
disease-free survival (10) 10
enzymology (10) 10
gene copy number (10) 10
in situ hybridization, fluorescence (10) 10
lung neoplasms - mortality (10) 10
lung neoplasms - surgery (10) 10
measuring or testing processes involving enzymes, nucleicacids or microorganisms (10) 10
metallurgy (10) 10
microbiology (10) 10
mutation or genetic engineering (10) 10
processes of preparing such compositions (10) 10
protein kinase inhibitors - therapeutic use (10) 10
spirits (10) 10
survival (10) 10
survival rate (10) 10
vinegar (10) 10
wine (10) 10
adenocarcinoma - genetics (9) 9
antineoplastic agents - therapeutic use (9) 9
carcinoma (9) 9
carcinoma, non-small-cell lung - mortality (9) 9
carcinoma, non-small-cell lung - surgery (9) 9
gene dosage (9) 9
hematology, oncology and palliative medicine (9) 9
investigating or analysing materials by determining theirchemical or physical properties (9) 9
lung neoplasms - diagnosis (9) 9
measuring (9) 9
nsclc (9) 9
physics (9) 9
survival analysis (9) 9
testing (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
carcinoma, non-small-cell lung - metabolism (8) 8
expression (8) 8
gene expression regulation, neoplastic (8) 8
lung neoplasms - therapy (8) 8
mutations (8) 8
prospective studies (8) 8
quinazolines - therapeutic use (8) 8
tumors (8) 8
afatinib (7) 7
analysis (7) 7
biomarkers, tumor - analysis (7) 7
breast-cancer (7) 7
cell lung-cancer (7) 7
crizotinib (7) 7
disease progression (7) 7
epidermal growth factor receptor (7) 7
lung cancer, small cell (7) 7
metastasis (7) 7
predictive value of tests (7) 7
previously treated patients (7) 7
tyrosine kinase inhibitors (7) 7
activating mutations (6) 6
carcinoma, squamous cell - genetics (6) 6
combination (6) 6
diagnosis (6) 6
gefitinib sensitivity (6) 6
health aspects (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 2012, Volume 77, pp. S2 - S2
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 2014, Volume 9, Issue 4, p. S6
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 716 - 722
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 09/2019, Volume 14, Issue 9, p. e196
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2006, Volume 24, Issue 31, pp. 5034 - 5042
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2174 - 2180
Purpose The purpose of this study was to characterize insulin-like growth factor-1 receptor (IGF1R) protein expression, mRNA expression, and gene copy number... 
BREAST-CANCER | ONCOLOGY | PATHWAY | IGFR-1 | ANTIBODY CP-751,871 | RESISTANCE | HETERODIMERIZATION | COMBINATION | GEFITINIB SENSITIVITY | CHEMOTHERAPY | ERLOTINIB | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Receptor, IGF Type 1 - analysis | Carcinoma, Non-Small-Cell Lung - chemistry | Lung Neoplasms - mortality | Tissue Array Analysis | Carcinoma, Squamous Cell - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | RNA, Messenger - analysis | Aneuploidy | Carcinoma, Squamous Cell - surgery | Male | Carcinoma, Squamous Cell - mortality | Time Factors | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Adenocarcinoma - chemistry | Lung Neoplasms - genetics | Carcinoma, Large Cell - chemistry | Carcinoma, Non-Small-Cell Lung - surgery | Lung Neoplasms - chemistry | Risk Assessment | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Squamous Cell - chemistry | In Situ Hybridization, Fluorescence | Treatment Outcome | Gene Dosage | Reverse Transcriptase Polymerase Chain Reaction | Carcinoma, Non-Small-Cell Lung - mortality | Receptor, IGF Type 1 - genetics | Disease-Free Survival | Carcinoma, Large Cell - surgery | Pulmonary Surgical Procedures | Lung Neoplasms - surgery | Aged | Neoplasm Staging | Adenocarcinoma - surgery | Original Reports | Thor19 | Bc8 | To20
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 26, pp. 3567 - 3573
Journal Article
British Journal of Cancer, ISSN 0007-0920, 2019, Volume 121, Issue 2, pp. 131 - 138
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and... 
ONCOLOGY | LUNG | CRIZOTINIB RESISTANCE | Slopes | Tropomyosin | Lung cancer | Non-small cell lung carcinoma | Pharmacology | Kinases | Lymphoma | Patients | Refractory materials | Inhibitors | Safety | Solid tumors | Pharmacokinetics | Protein-tyrosine kinase | Tumors | Targeted therapies
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 9, pp. 992 - +
Journal Article
Lung Cancer, ISSN 0169-5002, 10/2019, Volume 136, pp. 80 - 85
Lung cancer has the highest incidence and fatality among all cancers. Our research analyzed the expression of galectin-9 on non-small cell lung cancer (NSCLC)... 
PD-L1 | Galectin-9 | TILs | NSCLC | PD-1 | Immunohistochemistry | Medical colleges | Cell death | Analysis | Lung cancer, Small cell | T cells | Lung cancer, Non-small cell | Tumors
Journal Article
Nucleosides, Nucleotides and Nucleic Acids, ISSN 1525-7770, 10/2019, Volume 38, Issue 10, pp. 781 - 787
Journal Article